Patents by Inventor Ji Hee LIM

Ji Hee LIM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11983501
    Abstract: The present invention relates to an apparatus and method for automatically generating machine reading comprehension training data, and more particularly, to an apparatus and method for automatically generating and managing machine reading comprehension training data based on text semantic analysis. The apparatus for automatically generating machine reading comprehension training data according to the present invention includes a domain selection text collection unit configured to collect pieces of text data according to domains and subjects, a paragraph selection unit configured to select a paragraph using the pieces of collected text data and determine whether questions and correct answers are generatable, and a question and correct answer generation unit configured to generate questions and correct answers from the selected paragraph.
    Type: Grant
    Filed: October 7, 2021
    Date of Patent: May 14, 2024
    Assignee: ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE
    Inventors: Yong Jin Bae, Joon Ho Lim, Min Ho Kim, Hyun Kim, Hyun Ki Kim, Ji Hee Ryu, Kyung Man Bae, Hyung Jik Lee, Soo Jong Lim, Myung Gil Jang, Mi Ran Choi, Jeong Heo
  • Publication number: 20240141061
    Abstract: The present disclosure relates to an antibody binding specifically to CD55 or an antigen-binding fragment thereof; and a composition for preventing, treating and/or diagnosing cancer containing the same. The antibody of the present disclosure may be used as an effective therapeutic composition for various CD55-mediated diseases since it shows high binding ability and inhibitory effect for the CD55 protein which promotes tumor growth by inhibiting the complement immune mechanism. In addition, the antibody of the present disclosure may be usefully used as an effective therapeutic adjuvant that fundamentally removes drug resistance and remarkably improves therapeutic responsiveness in various diseases in which resistance to therapeutic agents with CDC (complement-dependent cytotoxicity) as a mechanism of action has been induced due to overexpression of CD55.
    Type: Application
    Filed: January 12, 2022
    Publication date: May 2, 2024
    Applicants: SG MEDICAL INC, KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, KOREA ATOMIC ENERGY RESEARCH INSTITUTE
    Inventors: Ji Chul LEE, Hye In PARK, Sung-Won MIN, Sung-Won MIN, Hyeong Sun KWON, Jae Cheong LIM, So Hee DOH, Eun Ha CHO, So-Young LEE, Sung Hee JUNG
  • Publication number: 20230210944
    Abstract: Proposed is an enteric-coated granular composition containing an ingredient derived from bee venom and lactic acid bacteria. The enteric-coated granular composition containing a bee venom-derived ingredient and lactic acid bacteria according to the present invention has an immune enhancing effect by increasing cytotoxic T cells, helper T cells, or B cells and the weight of lymph nodes; and a recovery effect on kidney injury by decreasing expression of cytokine TNF-?, IL-1? and NGAL.
    Type: Application
    Filed: October 21, 2022
    Publication date: July 6, 2023
    Inventors: Jung Keun PARK, Mi Ran KANG, Ji Hee LIM, Sir A LEE, Joo Yeon KIM, Choul Koo KIM, Kwan Kyu PARK, Hye Min GU, Seong Jae BAE, Mi Gyeong GWON, Hyun Jin AN